Top Page
CK Life Sciences International (Holdings), Inc.
(0775)
CK Life Sciences International (Holdings), Inc. (0775) vs. S&P 500 (SPY)
CK Life Sciences International (Holdings), Inc. Business Overview & Revenue Model
CK Life Sciences International (Holdings), Inc. Financial Statement Overview
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 5.32B | 5.28B | 5.40B | 4.94B | 4.97B | Gross Profit |
| 1.64B | 1.63B | 1.63B | 1.41B | 1.61B | EBIT |
| 223.85M | 339.63M | 336.06M | 247.85M | 376.32M | EBITDA |
| 624.75M | 469.51M | 449.14M | 353.62M | 475.21M | Net Income Common Stockholders |
| 17.25M | 131.96M | 162.80M | 125.23M | 181.74M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 676.16M | 704.13M | 902.47M | 971.71M | 713.14M | Total Assets |
| 11.25B | 11.27B | 11.73B | 11.98B | 10.71B | Total Debt |
| 5.93B | 5.95B | 6.21B | 6.19B | 5.63B | Net Debt |
| 5.27B | 5.25B | 5.32B | 5.23B | 4.93B | Total Liabilities |
| 7.06B | 7.11B | 7.23B | 7.26B | 6.54B | Stockholders Equity |
| 4.19B | 4.16B | 4.50B | 4.72B | 4.18B |
| Cash Flow | Free Cash Flow | |||
| 222.35M | 146.69M | 206.33M | 151.12M | 181.37M | Operating Cash Flow |
| 514.18M | 363.66M | 423.57M | 530.96M | 379.15M | Investing Cash Flow |
| -67.96M | -22.12M | -257.88M | -457.31M | -253.92M | Financing Cash Flow |
| -477.95M | -515.34M | -220.08M | 168.74M | -192.21M |
CK Life Sciences International (Holdings), Inc. Technical Analysis
CK Life Sciences International (Holdings), Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $66.04B | 14.33 | 13.20% | 5.99% | -9.60% | -27.18% | |
72 Outperform | $928.26B | 6.69 | 5.69% | 11.71% | 37.04% | ||
66 Neutral | $68.53B | 36.10 | 6.14% | 1.56% | 7.63% | -24.23% | |
65 Neutral | HK$8.17B | ― | -3.29% | ― | 3.76% | -833.33% | |
64 Neutral | HK$70.26B | 151.27 | 0.88% | 0.47% | ― | ― | |
52 Neutral | $5.21B | 3.55 | -41.91% | 2.83% | 15.12% | 0.42% | |
51 Neutral | $4.51B | ― | -18.09% | 1.26% | -24.30% | -10350.00% |
CK Life Sciences International (Holdings), Inc. Corporate Events
CK Life Sciences International (Holdings) Inc. announced its plans to present new data from preclinical studies of investigational cancer vaccines at the 2025 AACR Annual Meeting. The vaccines target proteins such as PRAME, PD-L1, B7-H3, and Claudin 6, which are associated with different cancers. The company is also making progress in developing an AI-powered platform to improve vaccine design. While the preclinical results are promising, the company has not yet commenced clinical trials, and stakeholders are advised to exercise caution.
CK Life Sciences International (Holdings) Inc. has announced its upcoming Annual General Meeting (AGM) scheduled for May 22, 2025, which will be held as a hybrid meeting both in-person and online. Key agenda items include the election of directors, appointment of auditors, and a resolution to grant the directors a mandate to issue additional shares, not exceeding ten percent of the current issued shares, with specific conditions on pricing and issuance period. This meeting is crucial for stakeholders as it will determine the company’s strategic directions and governance for the coming year.
CK Life Sciences International (Holdings) Inc. has announced promising preclinical results for its novel cancer vaccines targeting TROP2, a protein overexpressed in various aggressive cancers. The vaccines have shown impressive tumor growth inhibition in mice studies, particularly in breast and colorectal cancers, and the company aims to advance these vaccines into clinical trials. The potential commercialization of these vaccines could bring significant economic benefits, although clinical trials have not yet commenced, and patent approvals are pending.
CK Life Sciences International (Holdings), Inc. has announced a trading halt of its shares on the Hong Kong Stock Exchange as of April 10, 2025, pending a forthcoming announcement. This move indicates a significant development within the company, potentially impacting its market position and stakeholder interests.
CK Life Sciences International (Holdings) Inc. announced that it has restored its public float to above the minimum 25% threshold required by the Hong Kong Stock Exchange. This move ensures compliance with listing regulations and reflects the company’s commitment to maintaining transparency and shareholder value.
CK Life Sciences reported a loss of HK$126.6 million for 2024, primarily due to increased R&D investments and a decline in the fair value of its vineyard portfolio. The company is advancing its R&D efforts in non-opioid pain management solutions and therapeutic cancer vaccines, including a merger to form Dogwood Therapeutics for further development of Halneuron®. Additionally, CK Life Sciences is investing in liquid biopsy tests for early cancer detection, leveraging AI and cutting-edge technologies to enhance its cancer vaccine pipeline.
CK Life Sciences International (Holdings), Inc. has announced the composition of its Board of Directors and their respective roles and functions. The board includes a mix of executive and non-executive directors, with key figures such as LI Tzar Kuoi, Victor serving as Chairman, and KAM Hing Lam as President. The announcement also details the membership of various board committees, highlighting the company’s governance structure and commitment to oversight in areas such as audit, remuneration, nomination, sustainability, and executive management.
CK Life Sciences International (Holdings), Inc. announced a connected transaction involving a Debt Exchange Agreement with a Purchaser, converting a loan of US$19.5 million, including accrued interest, into equity shares. This transaction, which is a material variation to the original Loan Agreement, allows the company to hold approximately 10.8% of the Purchaser’s outstanding common stock, aiding the Purchaser in meeting Nasdaq’s equity requirements.
CK Life Sciences International (Holdings), Inc. announced that its public float is currently at approximately 24.99552%, slightly below the 25% minimum required by the Hong Kong Stock Exchange. The company plans to restore the public float to the requisite level by June 2025 and will update stakeholders accordingly. This development indicates a need for strategic adjustments to meet regulatory standards, with potential implications for investor relations and market confidence.